Clinical Trials Logo

Clinical Trial Summary

This research project proposes a novel approach to elucidate the biological adaptations associated with Cannabis Use Disorder and to assess whether such adaptations are predictive of higher drug craving in response to both drug cues and stressors in both the laboratory and real-world, and higher relapse risk and drug use in the real world.


Clinical Trial Description

The intent of this study is to recruit 25 treatment-seeking individuals with Cannabis Use Disorder (CUD) and 25 light users (<1 joint/week) to complete three guided imagery conditions (stress, cannabis, neutral) in inpatient research units. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability [HRV]) will be collected. Thereafter, individuals with CUD will begin one-month of drug counseling treatment coupled with surveys delivered via smartphones daily in the morning, evening, and at four random times during the day. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04116619
Study type Observational
Source Yale University
Contact
Status Completed
Phase
Start date February 1, 2021
Completion date February 1, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05726617 - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders N/A
Not yet recruiting NCT04139668 - Vivitrol Treatment for Cannabis Use Disorder Phase 2
Completed NCT01656707 - Adaptive Treatment for Adolescent Cannabis Use Disorders N/A
Completed NCT03204305 - Brain Imaging of Cannabinoid Receptors Early Phase 1
Completed NCT05005013 - A Teleheath tDCS Approach to Decrease Cannabis Use N/A
Recruiting NCT05292547 - Repetitive Transcranial Magnetic Stimulation to People With Cannabis Use Disorder (SToP-C-rTMS x CUD) N/A
Completed NCT02932215 - Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder Phase 1
Completed NCT03430050 - Progesterone for Cannabis Withdrawal Early Phase 1
Withdrawn NCT03629106 - Effects of Cannabis Abstinence on Symptomology and Cognition in Bipolar Disorder N/A
Completed NCT03334721 - Gabapentin for Bipolar & Cannabis Use Disorders Phase 2
Recruiting NCT04721353 - Reducing Cannabis Overuse With Prazosin Phase 4
Completed NCT03718520 - The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
Completed NCT03624933 - Effects of Cannabis Abstinence on Symptoms and Cognition in Depression N/A
Recruiting NCT05836207 - Rewards for Cannabis Abstinence-study N/A
Not yet recruiting NCT06114212 - Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder N/A
Recruiting NCT05855668 - Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment N/A
Recruiting NCT04517474 - Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use. N/A
Recruiting NCT05885542 - SCORE Emerging Adult Cannabis Use & Stress Phase 1/Phase 2
Not yet recruiting NCT06085222 - Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users Phase 1
Completed NCT03056482 - Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC) Phase 4